Yes it does matter

To be honest we’re not sure who said “Those who cannot remember the past are condemned to repeat it” but we know it wasn’t anyone at Abbott. Yesterday the company continued to backtrack from their initial comments that Libre2 would not just receive FDA approval but would garner this approval with an iCGM designation. Since Libre2 was submitted to the FDA the company who initially expressed supreme confidence has been backtracking off this initial confidence.

Now we really hate to do this, first because it makes us feel old and second because so many forget the past . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

© 2005 - 2020 Diabetic Investor, Inc., all rights reserved. Unless expressly permitted under your written license agreement, you are not authorized to forward or to otherwise copy our newsletter, or any portion thereof, by electronic means or otherwise. 17 U.S.C. §504 provides for statutory damages of up to $150,000 per infringement of a copyright and additional damages.